

Table 3. Continued

References	Study period	Study subjects				Category	Relative risk (95% CI)	P for trend	Confounding variables considered	Comments
		Type and source	Definition	Number of cases	Number of controls					
						Never	1.00			
						Sometimes	2.58 (0.80–8.33)			
						Frequently	12.47 (0.97–160.1)			
Akiyama et al. (38)	1997–2008	Hospital-based (Yokohama City University Hospital)	Cases: diagnosed as having esophageal squamous cell carcinoma Controls: patients who had undergone endoscopies as part of a health checkup	253 (age 38–86) (male 225, female 28)	253 (age 38–86) (male 225, female 28)	Regular drinking habit ^a	3.228 (2.028–5.138)	P<0.0001	Age/sex group matched	The detail of regular drinking habit was not described
Oze et al. (40)	2001–2005	Hospital-based (Aichi Cancer Center Hospital)	Cases: histologically confirmed esophageal cancer cases	265 (age 33–79) (male 235, female 30)	530 (36–78) (male 470, female 60)	Alcohol consumption ^a		Not described	Age/sex matched Adjusted for smoking, <i>ALDH2</i> genotype fruit and vegetable intake, hot beverage intake and body mass index Adjusted for facial flushing, smoking, fruit and vegetable intake, hot beverage intake and body mass index	Moderate drinker: <4 days/week High-moderate drinker: <46 g ethanol and ≥5 days/week Heavy drinker: ≥46 g ethanol and ≥5 days/week

Controls:
non-cancer
first-visit
outpatients at the
same hospital

Non-drinker	1.0
Moderate drinker	5.95 (2.56– 13.80)
High-moderate drinker	24.84 (10.29– 59.95)
Heavy drinker	95.98 (37.38– 246.44)
Alcohol consumption	
Non-drinker	1.0
Moderate drinker	2.34 (1.08– 5.08)
High-moderate drinker	7.75 (3.64– 16.50)
Heavy drinker	27.12 (12.38– 59.43)

NA, not available; ALDH2, aldehyde dehydrogenase-2; OR, odds ratio.
^aCategories from which the magnitude of association was judged.

Table 4. Summary of the association between alcohol drinking and esophageal cancer risk, cohort study

References	Study period	Study population						Magnitude of association
		Sex	Number of subjects	Age range (years)	Event	Number of incident cases or deaths	Category	
Hirayama (29)	1965–1981	Men	122 261	≥40	Death	438	Daily drinking	↑↑↑
		Women	142 857	≥40	Death	147	Daily drinking	↑↑↑
Sakata et al. (30)	1988–1999	Men	46 465	40–79	Death	100	Drinking status	↑↑↑
							Units/day	↑↑↑
							Years of drinking	↑↑↑
							Cum units/year	↑↑↑
Ishikawa et al. (31)	Cohort 1	Men	9008	≥40	Incidence	38	Daily drinking	↑↑↑
	1984–1992							
Ishiguro et al. (32)	Cohort 2	Men	17 715	40–64	Incidence	40	Daily drinking	↑↑↑
	1990–1997							
Ishiguro et al. (32)	Cohort 1	Men	60 876	40–69	Incidence	215	Drinking status	↑↑↑
	1993–2004						Ethanol/week	↑↑↑
	Cohort 2							
	1995–2004							

↑↑↑, strong positive association.

Table 5. Summary of the association between alcohol drinking and esophageal cancer risk, case-control study

References	Study period	Study subjects					Magnitude of association
		Sex	Age range (years)	Number of cases	Number of controls	Category	
Sasaki et al. (33)	1974–1979	Men	Not specified	145	285	Sake drink in	↑↑↑
		Women	Not specified	56	118	evenings	NA
Hanaoka et al. (34)	1989–1991	Men	Not specified	141	141	Freq. of alcohol drinking	↑↑↑
Takezaki et al. (35)	1988–1997	Men	40–79	346	11 936	Drinking status	↑↑↑
						Dose of alcohol consumption	
Matsuo et al. (44)	1999–2000	Men and women	40–76	102	241	Drinking status	↑↑↑
				(M: 86, F: 16)	(M: 118, F: 123)		
Yokoyama et al. (41)	2000–2001	Men	40–79	234	634	Drinking status	↑↑↑
Takagi et al. (39)	1990–1999	Women	17–87	34	178	Drinking status	↑↑↑
Yokoyama et al. (42)	2000–2004	Women	40–79	52	412	Drinking status	↑↑↑
Akiyama et al. (38)	1997–2008	Men and women	38–86	253	253	Drinking status	↑↑↑
				(M: 225, F: 28)	(M: 225, F: 28)		
Oze et al. (40)	2001–2005	Men and women	33–79	265	530	Dose of alcohol consumption	↑↑↑

↑↑↑, strong positive association; NA, not available.




Figure 1. Summary estimates of the association between alcohol drinking and esophageal cancer risk. RR, relative risk; M, male; F, female. The boxed area represents the contribution of each study (weight) to the meta-analysis.

ACKNOWLEDGEMENTS

I.O is an Awardee of Research Resident Fellowship from the Foundation for Promotion of Cancer Research (Japan) for the 3rd Term Comprehensive 10-year Strategy for Cancer Control.

Funding

This study was supported by Third Term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare, Japan.

Conflict of interest statement

None declared.

References

1. Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, et al. Carcinogenicity of alcoholic beverages. *Lancet Oncol* 2007;8:292-3.
2. IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 96. Alcoholic Beverage Consumption and Ethyl Carbamate (Urethane)*. Lyon, France: IARC 2010.
3. World Cancer Research Fund/American Institute for Cancer Research. *Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective*. Washington, DC: AICR 2007;157-71
4. Matsuo K, Hamajima N, Shinoda M, Hatooka S, Inoue M, Takezaki T, et al. Gene-environment interaction between an aldehyde dehydrogenase-2 (ALDH2) polymorphism and alcohol consumption for the risk of esophageal cancer. *Carcinogenesis* 2001;22:913-6.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55:74-108.
6. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. *Int J Epidemiol* 2000;29:645-54.
7. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the cancer incidence in five continents database. *Int J Epidemiol* 2001;30:1415-25.

8. Fernandes ML, Seow A, Chan YH, Ho KY. Opposing trends in incidence of esophageal squamous cell carcinoma and adenocarcinoma in a multi-ethnic Asian country. *Am J Gastroenterol* 2006;101:1430-6.
9. Shibata A, Matsuda T, Ajiki W, Sobue T. Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993-2001. *Jpn J Clin Oncol* 2008;38:464-8.
10. Inoue M, Tsuji I, Wakai K, Nagata C, Mizoue T, Tanaka K, et al. Evaluation based on systematic review of epidemiological evidence among Japanese populations: tobacco smoking and total cancer risk. *Jpn J Clin Oncol* 2005;35:404-11.
11. Inoue M, Wakai K, Nagata C, Mizoue T, Tanaka K, Tsuji I, et al. Alcohol drinking and total cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. *Jpn J Clin Oncol* 2007;37:692-700.
12. Mizoue T, Inoue M, Tanaka K, Tsuji I, Wakai K, Nagata C, et al. Tobacco smoking and colorectal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. *Jpn J Clin Oncol* 2006;36:25-39.
13. Mizoue T, Tanaka K, Tsuji I, Wakai K, Nagata C, Otani T, et al. Alcohol drinking and colorectal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. *Jpn J Clin Oncol* 2006;36:582-97.
14. Nagata C, Mizoue T, Tanaka K, Tsuji I, Wakai K, Inoue M, et al. Tobacco smoking and breast cancer risk: an evaluation based on a systematic review of epidemiological evidence among the Japanese population. *Jpn J Clin Oncol* 2006;36:387-94.
15. Nagata C, Mizoue T, Tanaka K, Tsuji I, Wakai K, Inoue M, et al. Alcohol drinking and breast cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. *Jpn J Clin Oncol* 2007;37:568-74.
16. Nishino Y, Inoue M, Tsuji I, Wakai K, Nagata C, Mizoue T, et al. Tobacco smoking and gastric cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. *Jpn J Clin Oncol* 2006;36:800-7.
17. Shimazu T, Tsuji I, Inoue M, Wakai K, Nagata C, Mizoue T, et al. Alcohol drinking and gastric cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. *Jpn J Clin Oncol* 2008;38:8-25.
18. Tanaka K, Tsuji I, Wakai K, Nagata C, Mizoue T, Inoue M, et al. Cigarette smoking and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among Japanese. *Jpn J Clin Oncol* 2006;36:445-56.
19. Tanaka K, Tsuji I, Wakai K, Nagata C, Mizoue T, Inoue M, et al. Alcohol drinking and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. *Jpn J Clin Oncol* 2008;38:816-38.
20. Wakai K, Inoue M, Mizoue T, Tanaka K, Tsuji I, Nagata C, et al. Tobacco smoking and lung cancer risk: an evaluation based on a systematic review of epidemiological evidence among the Japanese population. *Jpn J Clin Oncol* 2006;36:309-24.
21. Wakai K, Nagata C, Mizoue T, Tanaka K, Nishino Y, Tsuji I, et al. Alcohol drinking and lung cancer risk: an evaluation based on a

- systematic review of epidemiologic evidence among the Japanese population. *Jpn J Clin Oncol* 2007;37:168–74.
22. Inoue M, Sasazuki S, Wakai K, Suzuki T, Matsuo K, Shimazu T, et al. Green tea consumption and gastric cancer in Japanese: a pooled analysis of six cohort studies. *Gut* 2009;58:1323–32.
 23. Mizoue T, Inoue M, Wakai K, Nagata C, Shimazu T, Tsuji I, et al. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. *Am J Epidemiol* 2008;167:1397–406.
 24. Organization. WH. *WHO Technical Reports Series 916. Diet, Nutrition and Prevention of Chronic Diseases: Report of a Joint WHO/FAO Expert Consultation*. Geneva: WHO, 2003.
 25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ (Clinical research ed)* 2003;327:557–60.
 26. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50:1088–101.
 27. Kinjo Y, Cui Y, Akiba S, Watanabe S, Yamaguchi N, Sobue T, et al. Mortality risks of oesophageal cancer associated with hot tea, alcohol, tobacco and diet in Japan. *J Epidemiol/Jpn Epidemiol Assoc* 1998;8:235–43.
 28. Yang CX, Matsuo K, Ito H, Hirose K, Wakai K, Saito T, et al. Esophageal cancer risk by ALDH2 and ADH2 polymorphisms and alcohol consumption: exploration of gene-environment and gene-gene interactions. *Asian Pac J Cancer Prev* 2005;6:256–62.
 29. Hirayama T. *Life-style and Mortality. A Large-scale Census-based Cohort Study in Japan*. Basel, Switzerland: Karger 1990.
 30. Sakata K, Hoshiyama Y, Morioka S, Hashimoto T, Takeshita T, Tamakoshi A. Smoking, alcohol drinking and esophageal cancer: findings from the JACC Study. *J Epidemiol/Jpn Epidemiol Assoc* 2005;15 Suppl 2:S212–9.
 31. Ishikawa A, Kuriyama S, Tsubono Y, Fukao A, Takahashi H, Tachiya H, et al. Smoking, alcohol drinking, green tea consumption and the risk of esophageal cancer in Japanese men. *J Epidemiol/Jpn Epidemiol Assoc* 2006;16:185–92.
 32. Ishiguro S, Sasazuki S, Inoue M, Kurahashi N, Iwasaki M, Tsugane S. Effect of alcohol consumption, cigarette smoking and flushing response on esophageal cancer risk: a population-based cohort study (JPHC study). *Cancer Lett* 2009;275:240–6.
 33. Sasaki R, Aoki K, Takeda S. Contribution of dietary habits to esophageal cancer in Japan. *Prog Clin Biol Res* 1990;346:83–92.
 34. Hanaoka T, Tsugane S, Ando N, Ishida K, Kakegawa T, Isono K, et al. Alcohol consumption and risk of esophageal cancer in Japan: a case-control study in seven hospitals. *Jpn J Clin Oncol* 1994;24:241–6.
 35. Takezaki T, Shinoda M, Hatooka S, Hasegawa Y, Nakamura S, Hirose K, et al. Subsite-specific risk factors for hypopharyngeal and esophageal cancer (Japan). *Cancer Causes Control* 2000;11:597–608.
 36. Yokoyama A, Kato H, Yokoyama T, Tsujinaka T, Muto M, Omori T, et al. Genetic polymorphisms of alcohol and aldehyde dehydrogenases and glutathione S-transferase M1 and drinking, smoking, and diet in Japanese men with esophageal squamous cell carcinoma. *Carcinogenesis* 2002;23:1851–9.
 37. Yokoyama A, Kato H, Yokoyama T, Igaki H, Tsujinaka T, Muto M, et al. Esophageal squamous cell carcinoma and aldehyde dehydrogenase-2 genotypes in Japanese females. *Alcohol Clin Exp Res* 2006;30:491–500.
 38. Akiyama T, Inamori M, Iida H, Endo H, Hosono K, Yoneda K, et al. Macroscopic extent of gastric mucosal atrophy: increased risk factor for esophageal squamous cell carcinoma in Japan. *BMC Gastroenterol* 2009;9:34.
 39. Takagi A, Ajiki W, Tsukuma H. A case-control study to identify risk factors for female esophageal cancer in Osaka prefecture. *Kousei no Shihyou* 2003;50:33–8 (in Japanese).
 40. Oze I, Matsuo K, Hosono S, Ito H, Kawase T, Watanabe M, et al. Comparison between self-reported facial flushing after alcohol consumption and ALDH2 Glu504Lys polymorphism for risk of upper aerodigestive tract cancer in a Japanese population. *Cancer Sci* 2010;101:1875–80.
 41. Yokoyama T, Yokoyama A, Kato H, Tsujinaka T, Muto M, Omori T, et al. Alcohol flushing, alcohol and aldehyde dehydrogenase genotypes, and risk for esophageal squamous cell carcinoma in Japanese men. *Cancer Epidemiol Biomarkers Prev* 2003;12:1227–33.
 42. Yokoyama A, Omori T, Yokoyama T, Sato Y, Mizukami T, Matsushita S, et al. Risk of squamous cell carcinoma of the upper aerodigestive tract in cancer-free alcoholic Japanese men: an endoscopic follow-up study. *Cancer Epidemiol Biomarkers Prev* 2006;15:2209–15.
 43. Asakage T, Yokoyama A, Haneda T, Yamazaki M, Muto M, Yokoyama T, et al. Genetic polymorphisms of alcohol and aldehyde dehydrogenases, and drinking, smoking and diet in Japanese men with oral and pharyngeal squamous cell carcinoma. *Carcinogenesis* 2007;28:865–74.
 44. Matsuo K, Wakai K, Hirose K, Ito H, Saito T, Tajima K. Alcohol dehydrogenase 2 His47Arg polymorphism influences drinking habit independently of aldehyde dehydrogenase 2 Glu487Lys polymorphism: analysis of 2,299 Japanese subjects. *Cancer Epidemiol Biomarkers Prev* 2006;15:1009–13.
 45. Takeshita T, Mao XQ, Morimoto K. The contribution of polymorphism in the alcohol dehydrogenase beta subunit to alcohol sensitivity in a Japanese population. *Hum Genet* 1996;97:409–13.

Appendix

Research group members: Shoichiro Tsugane (principal investigator), Manami Inoue, Shizuka Sasazuki, Motoki Iwasaki, Tetsuya Otani (until 2006), Norie Sawada (since 2007), Taichi Shimazu (since 2007) (National Cancer Center, Tokyo); Ichiro Tsuji (since 2004), Yoshitaka Tsubono (in 2003) (Tohoku University, Sendai); Yoshikazu Nishino (until 2006) (Miyagi Cancer Research Institute, Natori, Miyagi); Akiko Tamakoshi (since 2010) (Aichi medical University, Aichi); Keitaro Matsuo (since 2006) (Aichi Cancer Center, Nagoya); Kenji Wakai (Nagoya University, Nagoya); Chisato Nagata (Gifu University, Gifu); Tetsuya Mizoue (National Center for Global Health and Medicine, Tokyo); Keitaro Tanaka (Saga University, Saga).

Original Article

Body Mass Index and Mortality From All Causes and Major Causes in Japanese: Results of a Pooled Analysis of 7 Large-Scale Cohort Studies

Shizuka Sasazuki¹, Manami Inoue¹, Ichiro Tsuji², Yumi Sugawara², Akiko Tamakoshi³, Keitaro Matsuo⁴, Kenji Wakai⁵, Chisato Nagata⁶, Keitaro Tanaka⁷, Tetsuya Mizoue⁸, and Shoichiro Tsugane¹, for the Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan*

¹Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan

²Division of Epidemiology, Department of Public Health and Forensic Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

³Department of Public Health, Aichi Medical University School of Medicine, Aichi, Japan

⁴Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan

⁵Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan

⁶Department of Epidemiology & Preventive Medicine, Gifu University School of Medicine, Gifu, Japan

⁷Department of Preventive Medicine, Saga Medical School, Faculty of Medicine, Saga University, Saga, Japan

⁸Department of Epidemiology and International Health, Research Institute National Center for Global Health and Medicine, Tokyo, Japan

Received December 8, 2010; accepted June 13, 2011; released online September 10, 2011

ABSTRACT

Background: We pooled data from 7 ongoing cohorts in Japan involving 353 422 adults (162 092 men and 191 330 women) to quantify the effect of body mass index (BMI) on total and cause-specific (cancer, heart disease, and cerebrovascular disease) mortality and identify optimal BMI ranges for middle-aged and elderly Japanese.

Methods: During a mean follow-up of 12.5 years, 41 260 deaths occurred. The Cox proportional hazards model was used to estimate hazard ratios (HRs) for each BMI category, after controlling for age, area of residence, smoking, drinking, history of hypertension, diabetes, and physical activity in each study. A random-effects model was used to obtain summary measures.

Results: A reverse-J pattern was seen for all-cause and cancer mortality (elevated risk only for high BMI in women) and a U- or J-shaped association was seen for heart disease and cerebrovascular disease mortality. For total mortality, as compared with a BMI of 23 to 25, the HR was 1.78 for 14 to 19, 1.27 for 19 to 21, 1.11 for 21 to 23, and 1.36 for 30 to 40 in men, and 1.61 for 14 to 19, 1.17 for 19 to 21, 1.08 for 27 to 30, and 1.37 for 30 to 40 in women. High BMI (≥ 27) accounted for 0.9% and 1.5% of total mortality in men and women, respectively.

Conclusions: The lowest risk of total mortality and mortality from major causes of disease was observed for a BMI of 21 to 27 kg/m² in middle-aged and elderly Japanese.

Key words: body mass index; mortality; cancer; heart disease; cerebrovascular disease

INTRODUCTION

Obesity is responsible for a serious health burden because of its association with type 2 diabetes mellitus, cardiovascular diseases, and some types of cancer.¹ As a measure of relative body weight, body mass index (BMI) is an easy-to-obtain, acceptable proxy for thinness and fatness, and has been found to be directly related to health risks and death rates in many

populations. According to the World Health Organization (WHO), the currently recommended BMI cut-off points for overweight and obesity are 25 kg/m² or greater and 30 kg/m² or greater, respectively.

Although these criteria were intended for international use, debate has centered on using the same cut-off points for Asian populations because of the high prevalence in those populations of type 2 diabetes mellitus and cardiovascular

*Research group members: Shoichiro Tsugane (principal investigator), Manami Inoue, Shizuka Sasazuki, Motoki Iwasaki, Tetsuya Otani (until 2006), Norie Sawada (since 2007), Taichi Shimazu, Taichi Yamaji (since 2007) (National Cancer Center, Tokyo); Ichiro Tsuji (since 2004), Yoshitaka Tsubono (in 2003) (Tohoku University, Sendai); Yoshikazu Nishino (Miyagi Cancer Research Institute, Natori, Miyagi); Kenji Wakai (Nagoya University, Nagoya); Keitaro Matsuo (since 2006) (Aichi Cancer Center, Nagoya); Chisato Nagata (Gifu University, Gifu); Tetsuya Mizoue (National Center for Global Health and Medicine, Tokyo); Keitaro Tanaka (Saga University, Saga); and Akiko Tamakoshi (Aichi Medical University, Nagakute, Aichi).

Address for correspondence: Shizuka Sasazuki, MD, Ph.D., Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan (e-mail: ssasazuk@ncc.go.jp).

Copyright © 2011 by the Japan Epidemiological Association

disease risk factors in individuals with a BMI less than 25 kg/m², as well as differences in the relationships between BMI, body fat percentage, and body fat distribution.² In 2002, a WHO expert consultation addressed this issue and concluded that there were no clear cut-off points for overweight and obesity in Asians. Based on international classifications, the consultation defined a BMI cut-off point of 23 kg/m² or greater as "increased risk" and a cut-off point of greater than 27.5 kg/m² as "high risk".³ However, in a recent, large pooled analysis of more than 1.1 million Asians, different patterns of association were observed between East Asians (Chinese, Japanese, and Koreans) and other Asians (Indians and Bangladeshis).⁴ Among East Asians, the lowest risk of death was seen among those with a BMI of 22.6 to 27.5, and the risk was elevated among those with a BMI higher or lower than that range. In the cohorts comprising Indians and Bangladeshis, the risk of death was increased for a BMI of 20.0 or less as compared with those with a BMI of 22.6 to 25.0, and there was no increase in risk associated with a high BMI. Considering the variation just within Asia, country-specific BMI cut-off points should be developed for public health interventions.

To date, many prospective cohort studies have evaluated the association between BMI and mortality in the Japanese population⁵⁻¹⁰; some showed a U-shaped^{7,9} or reverse J-shaped association,¹⁰ but others did not.^{5,6,8} These studies defined BMI categories differently and controlled for different confounding variables. In the present study, we pooled 7 cohort studies in Japan to clarify the role of relative body weight on total mortality and major causes of mortality (cancer, heart disease, and cerebrovascular disease) in the Japanese population. In the present analysis of more than 350 000 subjects we also aimed to identify an optimal BMI range for middle-aged and elderly Japanese.

METHODS

Study population

In 2006, the Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan initiated a pooling project using original data from major cohort studies to evaluate the association between lifestyle and major forms of cancer and mortality in Japanese. Topics for the pooled analysis were determined on the basis of discussions among all authors and were evaluated with respect to their scientific and public health importance.^{11,12} To maintain the quality and comparability of data, we established a priori inclusion criteria: namely, population-based cohort studies that (1) were conducted in Japan and started in the mid-1980s to mid-1990s, (2) included more than 30 000 participants, (3) obtained information on BMI calculated by height and weight reported in a validated questionnaire at baseline, and (4) collected any cause of mortality during the follow-up period. Seven ongoing studies that met these criteria were identified:

the Japan Public Health Center-based Prospective Study, Cohort I (JPHC-I)¹³; the Japan Public Health Center-Based Prospective Study, Cohort II (JPHC-II)¹³; the Japan Collaborative Cohort Study (JACC)¹⁴; the Miyagi Cohort Study (MIYAGI)¹⁵; the Ohsaki National Health Insurance Cohort Study (OHSAKI)¹⁶; the Three-Prefecture Aichi (3-pref AICHI)¹⁷; and the Takayama Study (TAKAYAMA).¹⁸ When analyzing individual results of each study, subjects with a previous history of any cancer, stroke, or myocardial infarction or with missing or implausible data (BMI <14 or ≥40) on BMI were excluded. Table 1 profiles the studies included in the analyses. Each study was approved by the appropriate institutional review board.

Follow-up and outcome ascertainment

Subjects were followed from the baseline survey (JPHC-I, 1990; JPHC-II, 1993–1994; JACC, 1988–1990; MIYAGI, 1990; OHSAKI, 1994; 3-pref AICHI, 1985; TAKAYAMA, 1992) to the last date of follow-up for any cause of mortality (JPHC-I, 2005; JPHC-II, 2005; JACC, 2006; MIYAGI, 2004 [2001 for cause-specific mortality]; OHSAKI, 2006; 3-pref AICHI, 2000; TAKAYAMA, 1999) in each study. Residence status, including survival, was confirmed through the residential registry.

Information on cause of death was obtained from death certificates provided by the Ministry of Health, Labour and Welfare with the permission of the Ministry of Internal Affairs and Communications. Cause of death was defined according to the International Classification of Disease, 10th version (ICD-10).¹⁹ Resident and death registration are required by law in Japan. The outcome of the present study was defined as all-cause mortality, including the 3 major causes of death among Japanese, specifically, cancer (ICD-10: C00–C97), heart disease (ICD-10: I20–I52), and cerebrovascular disease (ICD-10: I60–I69).

BMI assessment

Body weight and height were self-reported in the baseline questionnaire conducted at each study. BMI was calculated as weight divided by the square of the height (kg/m²). It was then divided into 7 categories using cut-off points that were identical among the studies, that is, 14 to 18.9, 19 to 20.9, 21 to 22.9, 23 to 24.9 (reference), 25 to 26.9, 27 to 29.9, and 30 to 39.9 kg/m². The cut-off points were derived from a US study (<21, 21.0–22.9, 23.0–24.9, 25.0–26.9, 27.0–29.9, and ≥30.0 kg/m²) that enrolled a reasonably large number of subjects and carefully accounted for methodologic problems.²⁰ Due to the large number of lean people, individuals with a BMI less than 21 kg/m² were subdivided into 2 groups in the present analysis: 14.0 to 18.9 kg/m² and 19 to 20.9 kg/m². This decision was based on our observation in the JPHC study that both BMI extremes are important determinants of total mortality⁹ and cancer occurrence and mortality.²¹

Statistical analysis

Time at risk was calculated as the duration from the date of the baseline survey in each study until the date of death or end of follow-up, whichever came first. In each study, sex-specific hazard ratios (HRs) and their 95% confidence intervals (CIs) were estimated for all-cause and cause-specific (cancer, heart disease, cerebrovascular disease, and other) mortality for each BMI category using the Cox proportional hazards model. Each study performed 2 types of adjustment for estimation of HRs: age (years, continuous) and area (JPHC-I, JPHC-II, and JACC only) (HR1). Further multivariate adjustments were conducted by including covariates in the model that were either known or suspected confounding factors, ie, cigarette smoking (for men: never smoker, past smoker, current smoker of 1 to 19 cigarettes/day or ≥ 20 cigarettes/day; for women: never smoker, past smoker, or current smoker), alcohol drinking (nondrinkers [never- and ex-drinker], occasional drinkers [less than once per week], regular drinkers [almost daily for OHSAKI and 3-pref AICHI; ≥ 5 days/week for JPHCI, JPHCII, and JACC; ≥ 5 times/week for MIYAGI; and ≥ 4 to 6 days/week for TAKAYAMA]), history of hypertension (no, yes), history of diabetes (no, yes), and leisure-time sports or physical exercise (less than almost daily, almost daily) (HR2). All included studies were population-based, and blood data were available for only a part of 1 study. We therefore used self-reported past history of diseases to control for hypertension and diabetes. We conducted an additional analysis that excluded deaths within 5 years from both the numerator and denominator (HR3).^{22,23} For men, we conducted stratified analysis by smoking status, namely, of never smokers and current smokers. An indicator term for missing data was created for each covariate.²⁴ SAS (version 9.1; SAS Institute, Cary, NC, USA) and Stata (version 11; Stata Corporation, College Station, TX, USA) statistical software were used for these analyses.

A random-effects model was used to obtain summary measures of the HRs from the individual studies for each category. The study-specific HRs were weighted by the inverse of the sum of their variance and the estimated between-studies variance component. These values from the individual studies were then combined using a random-effects model. The impact of heterogeneity was measured by using the I^2 statistic, which describes the proportion of total variation in study estimates that is due to heterogeneity. Although there is no universal rule to define mild, moderate, or severe heterogeneity, it is reasonable to assume that a value less than 30% represents mild heterogeneity and that a value greater than 50% represents substantial heterogeneity.²⁵ Stata software was used for the meta-analysis.

In addition, to express the impact of BMI on the risk of mortality, the population-attributable fraction (PAF) was estimated and expressed as a percentage.²⁶ Using HR2 and prevalence in each category, we calculated the PAF attributable to high BMI (≥ 27 kg/m² for men and women),

assuming subjects in these BMI categories moved to the reference category (23–25 kg/m²). The reference category was based on the BMI range in which total mortality was lowest for men and women, respectively. We applied this reference category to all end points, and when the HR was less than 1.0, the PAF was calculated as a minus value. This occurred in only 1 category: the PAF of cancer due to a BMI of 27 to 30 kg/m² in men was -0.10% , and together with the PAF due to a BMI of 30 to 40 (0.29%), the PAF of cancer due to high BMI (≥ 27 kg/m²) was 0.2%.

RESULTS

The present study included 353 422 adults (162 092 men and 191 330 women) from 7 ongoing large-scale, population-based, prospective studies in Japan (Table 1). During 4 399 108 person-years of follow-up (mean 12.5 years/person), 41 260 deaths were identified (25 944 men and 15 316 women), including 15 690 deaths from cancer (10 115 men and 5575 women), 5940 deaths from heart disease (3378 men and 2562 women), 5071 deaths from cerebrovascular disease (2820 men and 2251 women), and 14 451 deaths from other causes (8950 men and 5501 women). The baseline characteristics of the study subjects by BMI category have been previously published.^{4,5,7,8,20,26–28}

Table 2 summarizes the results of pooled analyses of BMI and mortality in men. When the model was fully adjusted for confounding variables (HR2), a reverse J-shaped association was observed for mortality from all causes, cancer, and other causes. Regarding these outcomes, a statistically significant increased risk was observed for all 3 categories among individuals with a BMI less than 23. As compared with a BMI range of 23 to 25 kg/m², the HRs for BMI ranges 14 to 19, 19 to 21, and 21 to 23 kg/m² were 1.78, 1.27, and 1.11 for all-cause death, 1.44, 1.23, and 1.10 for cancer death, and 2.15, 1.42, and 1.17 for other-cause death, respectively. The HR continued to decrease even for a BMI greater than 25 kg/m², and the BMI range 25 to 27 kg/m² seemed to be the lowest risk group for these outcomes. Increased risk among individuals with a high BMI was limited to those with a BMI of 30 to 40 kg/m² (obesity); the HR was 1.36 for all-cause death (statistically significant), 1.20 for cancer death (not statistically significant), and 1.29 for other-cause death (not statistically significant).

For heart disease and cerebrovascular disease, a U-shaped or J-shaped association was observed. A statistically significant increased risk was observed for both the high and low BMI ranges. The HR was similar or slightly higher for a high BMI; the HRs for a BMI of 14 to 19, 19 to 21, and 30 to 40 kg/m² were 1.45, 1.11, and 1.71 for heart disease and 1.53, 1.28, and 1.64 for cerebrovascular disease, respectively.

When subjects who died in the first 5 years of follow-up were excluded, most results were attenuated, but still significant (HR3). Through this process, the I^2 for the lowest

Table 1. Characteristics of the 7 cohort studies included in a pooled analysis of body mass index and risk of all-cause and major-cause mortality

Study	Population	Age (years) at baseline survey	Year(s) of baseline survey	Population size	Rate of response (%) to baseline questionnaire	Method of follow-up	The present pooled analysis						
							Age (years)	Last follow-up time	Mean duration of follow-up (years)	Size of cohort		Number of total deaths	
										Men	Women	Men	Women
JPHC-I	Japanese residents of 5 public health center areas in Japan	40–59	1990	61 595	82%	Death certificates	40–59	2005	14.2	23 156	26 104	2392	1194
JPHC-II	Japanese residents of 6 public health center areas in Japan	40–69	1993–1994	78 825	80%	Death certificates	40–69	2005	11.3	29 015	32 484	3672	1802
JACC	Residents of 45 areas throughout Japan	40–79	1988–1990	110 792	83%	Death certificates	40–79	2006	14.7	41 639	57 147	10 575	7351
MIYAGI	Residents of 14 municipalities in Miyagi Prefecture, Japan	40–64	1990	47 605	92%	Death certificates	40–64	2004 (all causes),	13.5	20 832	22 616	2097	1041
								2001 (cause-specific)				10.3	1409
OHSAKI	Residents of 14 municipalities in Miyagi Prefecture, Japan	40–79	1994	52 029	95%	Death certificates	40–79	2006	10.0	21 008	22 886	3675	2015
3-pref AICHI	Residents of 2 municipalities in Aichi Prefecture, Japan	40–103	1985	33 529	90%	Death certificates	40–103	2000	11.7	13 841	15 296	2516	1866
TAKAYAMA	Japanese residents of Takayama, Gifu, Japan	≥35	1992	31 552	85%	Death certificates	35–101	1999	6.9	12 601	14 797	1017	767
Total										162 092	191 330	25 944	16 036

Abbreviations: JPHC, Japan Public Health Center-based prospective Study; JACC, The Japan Collaborative Cohort Study; MIYAGI, The Miyagi Cohort Study; OHSAKI, Ohsaki National Health Insurance Cohort Study; 3-pref AICHI, The Three Prefecture Study - Aichi portion; TAKAYAMA, Takayama Study.

Table 2. Pooled analysis of BMI and mortality (Men)

	14-<19	19-<21	21-<23	23-<25	25-<27	27-<30	30-<40	Heterogeneity I squared (%) and P for the lowest category highest category	
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)		
All Causes									
Number of subjects (n = 162 092)	9933	28 571	44 035	42 354	23 238	11 448	2513		
Person-years 1 967 103	108 482	342 361	538 369	522 805	287 923	141 921	25 243		
Number of deaths (n = 25 944)	3162	5717	7022	5519	2728	1420	376		
Crude rate (per 100 000)	2914.77	1669.88	1304.31	1055.65	947.48	1000.56	1489.53		
Age-standardized rate (per 100 000)	2009.45	1483.13	1283.1	1144.92	1086.56	1205.09	1495.49		
Age- and area-adjusted (HR1) ^a	1.83	1.30	1.12	1.00	0.95	1.09	1.42	80.6%	46.6%
	(1.64–2.05)	(1.24–1.37)	(1.05–1.19)	(Reference)	(0.91–0.996)	(0.97–1.21)	(1.22–1.65)	(P < 0.0001)	(P = 0.081)
Multivariate-adjusted (HR2) ^b	1.78	1.27	1.11	1.00	0.94	1.07	1.36	77.1%	32.3%
	(1.60–1.98)	(1.22–1.33)	(1.04–1.18)	(Reference)	(0.90–0.99)	(0.97–1.17)	(1.19–1.55)	(P < 0.0001)	(P = 0.181)
Multivariate-adjusted, excl. early death (HR3) ^c	1.64	1.24	1.10	1.00	0.96	1.09	1.35	52.8%	59.4%
	(1.50–1.79)	(1.19–1.29)	(1.03–1.17)	(Reference)	(0.91–1.01)	(0.97–1.22)	(1.11–1.65)	(P = 0.048)	(P = 0.022)
Cancer									
Number of subjects (n = 162 092)	9933	28 571	44 035	42 354	23 238	11 448	2513		
Person-years 1 909 493	106 697	333 333	521 589	504 796	277 359	136 168	29 551		
Number of deaths (n = 10 115)	1022	2252	2873	2269	1056	516	127		
Crude rate (per 100 000)	957.85	675.60	550.82	449.49	380.73	378.94	429.76		
Age-standardized rate (per 100 000)	730.77	614.48	541.64	479.33	426.71	437.22	526.94		
Age- and area-adjusted (HR1) ^a	1.52	1.29	1.13	1.00	0.90	0.97	1.18	68.9%	27.8%
	(1.31–1.77)	(1.19–1.40)	(1.04–1.22)	(Reference)	(0.83–0.96)	(0.85–1.10)	(0.95–1.47)	(P = 0.004)	(P = 0.226)
Multivariate-adjusted (HR2) ^b	1.44	1.23	1.10	1.00	0.90	0.98	1.20	67.7%	27.2%
	(1.24–1.67)	(1.13–1.34)	(1.02–1.19)	(Reference)	(0.84–0.97)	(0.86–1.12)	(0.97–1.50)	(P = 0.005)	(P = 0.231)
Multivariate-adjusted, excl. early death (HR3) ^c	1.27	1.17	1.08	1.00	0.95	1.02	1.29	27.6%	0.0%
	(1.12–1.43)	(1.09–1.26)	(0.997–1.18)	(Reference)	(0.87–1.03)	(0.86–1.22)	(1.05–1.58)	(P = 0.218)	(P = 0.460)
Heart Disease									
Number of subjects (n = 162 092)	9933	28 571	44 035	42 354	23 238	11 448	2513		
Person-years 1 909 493	106 697	333 333	521 589	504 796	277 359	136 168	29 551		
Number of deaths (n = 3378)	383	671	887	725	411	237	64		
Crude rate (per 100 000)	358.96	201.30	170.06	143.62	148.18	174.05	216.57		
Age-standardized rate (per 100 000)	231.78	176.19	167.33	157.75	170.83	215.61	276.87		
Age- and area-adjusted (HR1) ^a	1.47	1.11	1.05	1.00	1.05	1.37	1.85	27.7%	0.0%
	(1.24–1.74)	(1.00–1.24)	(0.95–1.16)	(Reference)	(0.86–1.29)	(0.998–1.87)	(1.43–2.39)	(P = 0.217)	(P = 0.711)
Multivariate-adjusted (HR2) ^b	1.45	1.11	1.05	1.00	1.03	1.28	1.71	34.5%	0.0%
	(1.21–1.74)	(1.00–1.24)	(0.95–1.16)	(Reference)	(0.84–1.25)	(0.95–1.74)	(1.32–2.22)	(P = 0.164)	(P = 0.765)
Multivariate-adjusted, excl. early death (HR3) ^c	1.28	1.10	1.01	1.00	1.04	1.17	1.72	25.7%	13.4%
	(1.04–1.59)	(0.96–1.24)	(0.89–1.15)	(Reference)	(0.83–1.31)	(0.83–1.65)	(1.22–2.43)	(P = 0.232)	(P = 0.328)

Continued on next page.

Continued.

	14-<19	19-<21	21-<23	23-<25	25-<27	27-<30	30-<40	Heterogeneity I squared (%) and P for the	
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	lowest category	highest category
Cerebrovascular Disease									
Number of subjects (n = 162 092)	9933	28 571	44 035	42 354	23 238	11 448	2513		
Person-years 1 909 493	106 697	333 333	521 589	504 796	277 359	136 168	29 551		
Number of deaths (n = 2820)	332	625	737	605	309	162	50		
Crude rate (per 100 000)	311.16	187.50	141.30	119.85	111.41	118.97	169.20		
Age-standardized rate (per 100 000)	201.17	161.94	138.77	133.33	132.93	153.72	218.73		
Age- and area-adjusted (HR1) ^a	1.43	1.21	1.03	1.00	1.01	1.19	1.81	22.5%	0.0%
	(1.20–1.71)	(1.06–1.39)	(0.92–1.15)	(Reference)	(0.88–1.16)	(0.996–1.41)	(1.35–2.42)	(P = 0.257)	(P = 0.511)
Multivariate-adjusted (HR2) ^b	1.53	1.28	1.05	1.00	0.97	1.10	1.64	29.4%	0.0%
	(1.26–1.85)	(1.10–1.49)	(0.94–1.17)	(Reference)	(0.84–1.11)	(0.92–1.31)	(1.23–2.20)	(P = 0.204)	(P = 0.671)
Multivariate-adjusted, excl. early death (HR3) ^c	1.52	1.21	1.02	1.00	0.95	1.11	1.54	22.3%	4.9%
	(1.23–1.89)	(1.06–1.38)	(0.89–1.15)	(Reference)	(0.75–1.20)	(0.91–1.36)	(1.06–2.24)	(P = 0.259)	(P = 0.391)
Other Causes									
Number of subjects (n = 162 092)	9933	28 571	44 035	42 354	23 238	11 448	2513		
Person-years 1 909 493	106 697	333 333	521 589	504 796	277 359	136 168	29 551		
Number of deaths (n = 8950)	1388	2047	2347	1751	861	448	108		
Crude rate (per 100 000)	1300.87	614.10	449.97	346.87	310.43	329.00	365.46		
Age-standardized rate (per 100 000)	853.68	538.23	443.38	380.67	361.97	362.07	370.2		
Age- and area-adjusted (HR1) ^a	2.49	1.43	1.18	1.00	0.94	1.08	1.35	70.9%	53.0%
	(2.14–2.90)	(1.33–1.55)	(1.08–1.29)	(Reference)	(0.85–1.04)	(0.97–1.20)	(1.00–1.83)	(P = 0.002)	(P = 0.047)
Multivariate-adjusted (HR2) ^b	2.15	1.42	1.17	1.00	0.93	1.05	1.29	65.6%	52.4%
	(2.10–2.79)	(1.32–1.54)	(1.07–1.28)	(Reference)	(0.84–1.03)	(0.95–1.17)	(0.95–1.74)	(P = 0.008)	(P = 0.050)
Multivariate-adjusted, excl. early death (HR3) ^c	2.31	1.43	1.16	1.00	0.93	1.10	1.22	53.0%	51.2%
	(1.99–2.69)	(1.30–1.57)	(1.08–1.25)	(Reference)	(0.84–1.02)	(0.98–1.24)	(0.85–1.76)	(P = 0.047)	(P = 0.056)

^aAdjusted for age (years, continuous) and area (for JPHC-I, JPHC-II, and JACC only) (HR1).

^bFurther adjusted for cigarette smoking (never smoker, past smoker, current smoker of 1–19 cigarettes/day or ≥20 cigarettes/day), alcohol drinking (nondrinkers [never- or ex-drinker], occasional drinkers (less than once per week), regular drinkers (almost daily for OHSAKI and 3-pref AICHI; ≥5 days/week for JPHCI, JPHCII, and JACC; ≥5 times/week for MIYAGI; and ≥4–6 days/week for TAKAYAMA), history of hypertension (no, yes), history of diabetes (no, yes), and leisure-time sports or physical exercise (less than almost daily, almost daily) (HR2).

^cExcluding deaths within 5 years (HR3). Bold text: P < 0.05.

category improved, which suggests that different conditions of early death across studies were the main reason for the heterogeneity seen among individuals with a lower BMI. Due to the relatively small number of subjects in the highest BMI category, the same process increased the I^2 in some outcomes for that category.

In women, a reverse J-shaped association was also observed for all-cause and other-cause mortality, but not for cancer (Table 3). For all-cause mortality, after fully adjusting for potential confounding factors (HR2) and using a BMI range of 23 to 25 kg/m² as the basis for comparison, the HRs for BMI ranges 14 to 19, 19 to 21, 27 to 30, and 30 to 40 kg/m² were estimated as 1.61, 1.17, 1.08, and 1.37, respectively. For cancer, a statistically significant increased risk was observed only for obesity, and there was no evidence of increased risk at any lower BMI range. After fully adjusting for confounding factors (HR2) and comparing with BMI range 23 to 25 kg/m², the HR for BMI range 30 to 40 kg/m² was 1.25. As with men, a U-shaped or J-shaped association was observed for heart disease and cerebrovascular disease in women. The risk elevation at lower and higher BMIs was more apparent for heart disease: the HRs for BMI ranges 14 to 19 and 30 to 40 kg/m² were 1.77 and 1.79 for heart disease and 1.44 and 1.30 for cerebrovascular disease, respectively. For all-cause and other-cause mortality, exclusion of early deaths slightly attenuated the results, but they remained significant. Furthermore, heterogeneity seen in the lowest category became nonsignificant.

When men were stratified by smoking status, the association between mortality and low BMI was generally more pronounced among current smokers than among never smokers (Table 4). This modification effect was most pronounced in cancer mortality, for which the observed risk elevation in the low BMI range disappeared among never smokers but remained among current smokers. The HRs for BMI ranges 14 to 19, 19 to 21, and 21 to 23 kg/m² were 1.05, 0.96, and 0.95, respectively, for never smokers and 1.49, 1.23, and 1.11 for current smokers. The heterogeneity in outcomes may be due in part to the relatively small sample size in the stratified analysis, and the results may not affect the above findings.

The data suggest that approximately 0.9% and 1.5% of total deaths were attributable to a high BMI (≥ 27 kg/m²) in men and women, respectively, as were 0.2% and 1.0% of cancer deaths, 2.8% and 2.7% of heart disease deaths, and 1.5% and 1.9% of cerebrovascular deaths.

DISCUSSION

In this pooled analysis of more than 350 000 Japanese, an elevated risk of all-cause mortality for both high and low BMI levels was observed in both sexes. This association remained after excluding early deaths during follow-up and after restricting the analysis to never smokers (in men). The results conform with most previous cohort studies in Japan,

which showed a U-shaped^{7,9} or reverse J-shaped association.¹⁰ Other studies showed no obvious increase in risk due to obesity in men^{5,8} or women,⁶ due to the older age of the subjects or the small number of subjects in the respective categories. All-cause mortality was lowest at a BMI range of 23 to 27 kg/m² in men and 21 to 27 kg/m² in women. Above this range, a significant increase in risk was observed only at a BMI range of 30 to 40 kg/m² in men and 27 kg/m² or higher in women. Men with a BMI of 27 to 30 kg/m² had a slightly elevated risk, which was not statistically significant. Four of 7 individual studies included in the pooled analysis showed an elevated risk, and among these, 3 found a statistically significant association; the HR range was 1.13 to 1.36. Therefore, we believe that a BMI greater than 27 kg/m² should be defined as a high-risk group for overall mortality in both men and women and that it is not necessary to set a higher or lower cut-off point in this population.

Cancer accounted for 37% (39% in men and 35% in women) of overall deaths. The association of BMI with cancer was similar to that observed for BMI and all-cause mortality in men. It has been observed in many studies that low BMI is associated with increased risk of cancer.^{21,29,30} As the effect-measure modification by cigarette smoking suggests, the risk elevation with low BMI in men is probably mostly due to smoking-related cancers (eg, cancers of the lung and esophagus, among others). In this population, most women were nonsmokers and thus no risk elevation was observed among women with a low BMI. Evidence of a positive association between high BMI and cancer risk comes mainly from Western populations, as shown in the Cancer Prevention Study-II³¹⁻³⁴ and the Million Women Study.^{35,36} Among previous cohort studies conducted in Japan, only 1 showed a statistically significant positive association between high BMI and cancer incidence in women, which was attributed to cancers of the breast (postmenopausal), endometrium, gallbladder, and colorectum.³⁷ That study and another study²¹ suggested that men were also at increased risk, and another study found that both men and women were at increased risk.³⁰ However, none of these findings were statistically significant. This may be due to the smaller proportion of overweight people in Japan as compared with Western countries. By pooling data, the present study revealed that obesity does increase the risk of mortality from cancer, although the contribution to the overall cancer burden was small.

For heart disease and cerebrovascular disease, a U- or J-shaped association was observed among men and women. Many epidemiologic studies have shown that obesity is a significant risk factor for developing heart disease and cerebrovascular disease. A continuous positive association was observed between BMI and the incidences of ischemic heart disease and stroke³⁸ and mortality²⁹ in collaborative analyses of prospective studies involving 310 000 participants from the Asia-Pacific region and 900 000 participants mainly from Western Europe and North America, respectively. In

Table 3. Pooled analysis of BMI and mortality (Women)

		14-<19	19-<21	21-<23	23-<25	25-<27	27-<30	30-<40	Heterogeneity I squared (%) and P for the lowest category highest category	
		HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)		
All Causes										
Number of subjects	(n = 191 303)	15 027	34 289	50 450	44 316	26 341	16 066	4814		
Person-years	2 432 005	176 627	426 608	644 023	572 803	342 343	207 994	61 606		
Number of deaths	(n = 16 036)	2302	2929	3702	3155	2081	1341	526		
Crude rate (per 100 000)		1303.32	686.58	574.82	550.80	607.87	644.73	853.81		
Age-standardized rate (per 100 000)		941.03	671.12	602.87	587.28	623.57	662.05	861.61		
Age- and area-adjusted (HR1) ^a		1.57	1.15	1.03	1.00	1.06	1.15	1.51	0.0%	0.0%
		(1.49-1.66)	(1.08-1.22)	(0.97-1.09)	(Reference)	(0.997-1.13)	(1.08-1.23)	(1.37-1.65)	(P = 0.436)	(P = 0.739)
Multivariate-adjusted (HR2) ^b		1.61	1.17	1.03	1.00	1.04	1.08	1.37	0.0%	0.0%
		(1.53-1.71)	(1.11-1.23)	(0.98-1.09)	(Reference)	(0.98-1.10)	(1.02-1.16)	(1.24-1.50)	(P = 0.728)	(P = 0.800)
Multivariate-adjusted, excl. early death (HR3) ^c		1.55	1.17	1.03	1.00	1.07	1.10	1.34	0.0%	50.5%
		(1.45-1.65)	(1.10-1.24)	(0.98-1.09)	(Reference)	(0.95-1.21)	(1.03-1.18)	(1.17-1.54)	(P = 0.643)	(P = 0.059)
Cancer										
Number of subjects	(n = 191 303)	15 027	34 289	50 450	44 316	26 341	16 066	4814		
Person-years	2 359 991	173 647	416 348	626 108	554 620	329 853	200 022	59 393		
Number of deaths	(n = 5575)	554	970	1352	1244	789	491	175		
Crude rate (per 100 000)		319.04	232.98	215.94	224.30	239.20	245.47	294.65		
Age-standardized rate (per 100 000)		267.45	235.79	223.67	231.51	237.09	241.52	289.2		
Age- and area-adjusted (HR1) ^a		1.13	1.01	1.01	1.00	1.04	1.07	1.30	56.8%	0.0%
		(0.95-1.35)	(0.92-1.10)	(0.90-1.13)	(Reference)	(0.95-1.13)	(0.96-1.19)	(1.11-1.52)	(P = 0.031)	(P = 0.909)
Multivariate-adjusted (HR2) ^b		1.12	1.00	1.00	1.00	1.03	1.05	1.25	59.1%	0.0%
		(0.93-1.35)	(0.92-1.09)	(0.90-1.12)	(Reference)	(0.94-1.13)	(0.94-1.17)	(1.07-1.47)	(P = 0.023)	(P = 0.935)
Multivariate-adjusted, excl. early death (HR3) ^c		1.10	1.00	1.00	1.00	1.04	1.11	1.28	36.1%	0.0%
		(0.92-1.31)	(0.91-1.11)	(0.88-1.13)	(Reference)	(0.93-1.15)	(0.98-1.25)	(1.07-1.54)	(P = 0.153)	(P = 0.988)
Heart Disease										
Number of subjects	(n = 191 303)	15 027	34 289	50 450	44 316	26 341	16 066	4814		
Person-years	2 359 991	173 647	416 348	626 108	554 620	329 853	200 022	59 393		
Number of deaths	(n = 2562)	385	429	548	423	300	381	96		
Crude rate (per 100 000)		221.71	103.04	87.52	76.27	90.95	190.48	161.64		
Age-standardized rate (per 100 000)		141.27	97.84	92.88	83.64	96.36	102.26	167.38		
Age- and area-adjusted (HR1) ^a		1.62	1.26	1.10	1.00	1.15	1.26	2.10	7.2%	0.0%
		(1.38-1.91)	(0.98-1.62)	(0.97-1.25)	(Reference)	(0.99-1.33)	(1.03-1.55)	(1.68-2.63)	(P = 0.373)	(P = 0.759)
Multivariate-adjusted (HR2) ^b		1.77	1.32	1.11	1.00	1.11	1.15	1.79	23.8%	0.0%
		(1.45-2.15)	(1.02-1.70)	(0.98-1.27)	(Reference)	(0.96-1.29)	(0.91-1.44)	(1.43-2.24)	(P = 0.247)	(P = 0.790)
Multivariate-adjusted, excl. early death (HR3) ^c		1.56	1.20	1.11	1.00	1.11	1.10	1.88	11.5%	9.7%
		(1.26-1.91)	(0.98-1.48)	(0.96-1.28)	(Reference)	(0.93-1.31)	(0.81-1.50)	(1.41-2.51)	(P = 0.342)	(P = 0.355)

Continued on next page.

Continued.

	14-<19	19-<21	21-<23	23-<25	25-<27	27-<30	30-<40	Heterogeneity I squared (%) and P for the	
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	lowest category	highest category
Cerebrovascular Disease									
Number of subjects (n = 191 303)	15 027	34 289	50 450	44 316	26 341	16 066	4814		
Person-years 2 359 991	173 647	416 348	626 108	554 620	329 853	200 022	59 393		
Number of deaths (n = 2251)	345	397	467	455	288	220	79		
Crude rate (per 100 000)	198.68	95.35	74.59	82.04	87.31	109.99	133.01		
Age-standardized rate (per 100 000)	137.28	92.44	78.75	89.87	91.29	117.61	134.98		
Age- and area-adjusted (HR1) ^a	1.36	1.02	0.87	1.00	0.99	1.26	1.52	50.0%	0.0%
	(1.06–1.74)	(0.86–1.20)	(0.75–1.01)	(Reference)	(0.84–1.18)	(1.01–1.58)	(1.20–1.94)	(P = 0.062)	(P = 0.957)
Multivariate-adjusted (HR2) ^b	1.44	1.08	0.88	1.00	0.94	1.15	1.30	55.9%	0.0%
	(1.10–1.88)	(0.91–1.28)	(0.76–1.03)	(Reference)	(0.79–1.13)	(0.93–1.41)	(1.02–1.65)	(P = 0.034)	(P = 0.981)
Multivariate-adjusted, excl. early death (HR3) ^c	1.32	1.07	0.88	1.00	0.95	1.14	1.52	50.3%	0.0%
	(0.95–1.84)	(0.88–1.29)	(0.72–1.06)	(Reference)	(0.80–1.13)	(0.92–1.42)	(1.16–1.99)	(P = 0.060)	(P = 0.959)
Other Causes									
Number of subjects (n = 191 303)	15 027	34 289	50 450	44 316	26 341	16 066	4814		
Person-years 2 359 991	173 647	416 348	626 108	554 620	329 853	200 022	59 393		
Number of deaths (n = 5501)	1008	1089	1264	957	641	389	153		
Crude rate (per 100 000)	580.49	261.56	201.88	172.55	194.33	194.48	257.61		
Age-standardized rate (per 100 000)	410.16	251.81	23.32	187.3	202.61	201.71	264.17		
Age- and area-adjusted (HR1) ^a	2.27	1.40	1.14	1.00	1.10	1.12	1.45	61.6%	0.0%
	(1.91–2.69)	(1.19–1.64)	(1.00–1.29)	(Reference)	(0.95–1.28)	(0.99–1.26)	(1.22–1.73)	(P = 0.016)	(P = 0.936)
Multivariate-adjusted (HR2) ^b	2.32	1.44	1.15	1.00	1.08	1.05	1.31	52.7%	0.0%
	(1.98–2.72)	(1.23–1.68)	(1.02–1.29)	(Reference)	(0.94–1.24)	(0.94–1.19)	(1.10–1.56)	(P = 0.048)	(P = 0.894)
Multivariate-adjusted, excl. early death (HR3) ^c	2.08	1.39	1.14	1.00	1.05	1.08	1.30	13.3%	0.0%
	(1.83–2.36)	(1.19–1.63)	(0.99–1.31)	(Reference)	(0.94–1.17)	(0.95–1.23)	(1.07–1.57)	(P = 0.328)	(P = 0.632)

^aAdjusted for age (years, continuous) and area (for JPHC-I, JPHC-II, and JACC only) (HR1).

^bFurther adjusted for cigarette smoking (never smoker, past smoker, or current smoker), alcohol drinking (nondrinkers [never- or ex-drinker], occasional drinkers (less than once per week), regular drinkers (almost daily for OHSAKI and 3-pref AICHI; ≥5 days/week for JPHCI, JPHCII, and JACC; ≥5 times/week for MIYAGI; and ≥4–6 days/week for TAKAYAMA), history of hypertension (no, yes), history of diabetes (no, yes), and leisure-time sports or physical exercise (less than almost daily, almost daily) (HR2).

^cExcluding deaths within 5 years (HR3). Bold text: P < 0.05.

Table 4. Pooled analysis of BMI and mortality, stratified by smoking status (Men)

		14-<19	19-<21	21-<23	23-<25	25-<27	27-<30	30-<40	Heterogeneity I squared (%) and P for the lowest category highest category	
		HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)		
All Causes										
Never smokers, multivariate-adjusted ^a		1.48 (1.25-1.77)	1.16 (0.996-1.34)	0.98 (0.89-1.08)	1.00 (Reference)	0.91 (0.80-1.04)	1.05 (0.90-1.23)	1.42 (0.99-2.02)	32.9% (P = 0.177)	54.8% (P = 0.039)
Number of subjects	(n = 32 227)	1479	4527	8111	9060	5481	2899	670		
Person-years	405 361	17 107	55 839	102 982	114 276	69 710	37 126	8322		
Number of deaths	(n = 4422)	417	784	1110	1048	589	362	112		
Crude rate (per 100 000)		2437.61	1404.04	1077.86	917.08	844.93	975.07	1345.83		
Current smokers, multivariate-adjusted ^a		1.68 (1.50-1.88)	1.22 (1.16-1.29)	1.09 (1.04-1.15)	1.00 (Reference)	0.96 (0.90-1.03)	1.06 (0.98-1.16)	1.40 (1.21-1.64)	63.5% (P = 0.012)	0.0% (P = 0.780)
Number of subjects	(n = 85 659)	5994	17 168	24 400	20 958	10 816	5186	1137		
Person-years	1 039 570	66 679	206 925	297 395	258 013	132 793	63 968	13 797		
Number of cases	(n = 14 191)	1828	3353	3960	2846	1363	662	179		
Crude rate (per 100 000)		2741.49	1620.39	1331.56	1103.05	1026.41	1034.89	1297.39		
Cancer										
Never smokers, multivariate-adjusted ^a		1.05 (0.81-1.36)	0.96 (0.81-1.15)	0.95 (0.82-1.11)	1.00 (Reference)	0.80 (0.61-1.04)	0.97 (0.77-1.21)	1.33 (0.91-1.94)	5.5% (P = 0.385)	0.0% (P = 0.874)
Number of subjects	(n = 32 227)	1479	4527	8111	9060	5481	2899	670		
Person-years	389 623	16 886	54 538	100 100	106 911	67 275	35 848	8066		
Number of deaths	(n = 1277)	90	211	340	345	162	99	30		
Crude rate (per 100 000)		532.99	386.88	339.66	322.70	240.80	276.16	371.92		
Current smokers, multivariate-adjusted ^a		1.49 (1.23-1.81)	1.23 (1.12-1.36)	1.11 (1.02-1.20)	1.00 (Reference)	0.97 (0.83-1.13)	0.98 (0.85-1.12)	1.30 (0.95-1.78)	68.5% (P = 0.004)	27.7% (P = 0.227)
Number of subjects	(n = 85 659)	5994	17 168	24 400	20 958	10 816	5186	1137		
Person-years	1 004 029	65 435	201 068	287 194	248 306	127 677	61 163	13 186		
Number of cases	(n = 5845)	664	1425	1701	1194	557	242	62		
Crude rate (per 100 000)		1014.74	708.72	592.28	480.86	436.26	395.67	470.19		
Heart Disease										
Never smokers, multivariate-adjusted ^a		1.36 (0.77-2.41)	1.11 (0.83-1.48)	0.93 (0.72-1.20)	1.00 (Reference)	1.09 (0.79-1.52)	1.35 (0.84-2.18)	1.93 (1.01-3.67)	41.4% (P = 0.129)	13.1% (P = 0.331)
Number of subjects	(n = 32 227)	1479	4527	8111	9060	5481	2899	670		
Person-years	389 623	16 886	54 538	100 100	106 911	67 275	35 848	8066		
Number of deaths	(n = 515)	46	89	124	120	78	45	13		
Crude rate (per 100 000)		272.42	163.19	123.88	112.24	115.94	125.53	161.16		
Current smokers, multivariate-adjusted ^a		1.27 (1.03-1.56)	0.98 (0.82-1.18)	0.99 (0.83-1.18)	1.00 (Reference)	1.10 (0.91-1.34)	1.25 (0.92-1.71)	1.81 (1.18-2.77)	14.4% (P = 0.320)	17.1% (P = 0.300)
Number of subjects	(n = 85 659)	5994	17 168	24 400	20 958	10 816	5186	1137		
Person-years	1 004 029	65 435	201 068	287 194	248 306	127 677	61 163	13 186		
Number of cases	(n = 1865)	211	380	514	391	222	115	32		
Crude rate (per 100 000)		322.45	188.99	178.97	157.47	173.88	188.02	242.68		

Continued on next page.

Continued.

	14-<19 HR (95% CI)	19-<21 HR (95% CI)	21-<23 HR (95% CI)	23-<25 HR (95% CI)	25-<27 HR (95% CI)	27-<30 HR (95% CI)	30-<40 HR (95% CI)	Heterogeneity I squared (%) and P for the lowest category	Heterogeneity I squared (%) and P for the highest category
Cerebrovascular Disease									
Never smokers, multivariate-adjusted ^a	1.32 (0.91–1.93)	1.32 (0.90–1.93)	0.99 (0.76–1.29)	1.00 (Reference)	1.10 (0.81–1.49)	1.23 (0.85–1.77)	2.61 (1.35–5.04)	0.0% (P = 0.851)	41.2% (P = 0.147)
Number of subjects (n = 32 227)	1479	4527	8111	9060	5481	2899	670		
Person-years	389 623	54 538	100 100	106 911	67 275	35 848	8066		
Number of deaths (n = 493)	43	92	119	109	73	42	15		
Crude rate (per 100 000)	254.65	168.69	118.88	101.95	108.51	117.16	185.96		
Current smokers, multivariate-adjusted ^a	1.55 (1.28–1.87)	1.20 (0.99–1.47)	1.02 (0.87–1.19)	1.00 (Reference)	0.98 (0.80–1.20)	1.10 (0.85–1.44)	1.41 (0.75–2.68)	0.0% (P = 0.611)	31.0% (P = 0.203)
Number of subjects (n = 85 659)	5994	17 168	24 400	20 958	10 816	5186	1137		
Person-years	1 004 029	65 435	287 194	248 306	127 677	61 163	13 186		
Number of cases (n = 1430)	193	341	381	288	141	70	16		
Crude rate (per 100 000)	294.95	169.59	132.66	115.99	110.43	114.45	121.34		
Other Causes									
Never smokers, multivariate-adjusted ^a	1.99 (1.53–2.59)	1.28 (1.02–1.61)	1.00 (0.79–1.28)	1.00 (Reference)	0.88 (0.72–1.09)	1.05 (0.81–1.37)	1.02 (0.65–1.60)	32.7% (P = 0.178)	0.0% (P = 0.554)
Number of subjects (n = 32 227)	1479	4527	8111	9060	5481	2899	670		
Person-years	389 623	54 538	100 100	106 911	67 275	35 848	8066		
Number of deaths (n = 1434)	187	288	357	317	163	101	21		
Crude rate (per 100 000)	1107.43	528.07	356.64	296.51	242.29	281.74	260.34		
Current smokers, multivariate-adjusted ^a	2.24 (1.93–2.60)	1.35 (1.23–1.49)	1.16 (1.03–1.30)	1.00 (Reference)	0.93 (0.80–1.08)	1.10 (0.94–1.28)	1.51 (1.06–2.15)	40.5% (P = 0.121)	33.8% (P = 0.170)
Number of subjects (n = 85 659)	5994	17 168	24 400	20 958	10 816	5186	1137		
Person-years	1 004 029	65 435	287 194	248 306	127 677	61 163	13 186		
Number of cases (n = 4627)	738	1120	1245	863	397	208	56		
Crude rate (per 100 000)	1127.83	557.03	433.51	347.55	310.94	340.08	424.69		

^aAdjusted for age (years, continuous) and area (for JPHC-I, JPHC-II, and JACC only), cigarette smoking (never smoker, past smoker, current smoker of 1–19 cigarettes/day or ≥20 cigarettes/day), alcohol drinking (nondrinkers [never- or ex-drinker], occasional drinkers (less than once per week), regular drinkers (almost daily for OHSAKI and 3-pref AICHI; ≥5 days/week for JPHCI, JPHCII, and JACC; ≥5 times/week for MIYAGI; and ≥4–6 days/week for TAKAYAMA), history of hypertension (no, yes), history of diabetes (no, yes), and leisure-time sports or physical exercise (less than almost daily, almost daily).

particular, dyslipidemia, diabetes mellitus, and hypertension are positively related to obesity.^{39–41} These intermediate factors related to the disease may be largely accounted for by the elevated risk associated with a high BMI. However, the elevated risk was still significant even after controlling for histories of diabetes and hypertension (HR2). This suggests that another mechanism not explained by these factors might exist within the pathway. Funada et al and Cui et al reported an elevated risk of ischemic heart disease and hemorrhagic stroke not only among individuals with a high BMI, but also among those with a low BMI.^{27,28} Several studies identified an association between low serum cholesterol level and hemorrhagic stroke.^{42,43} Serum cholesterol level is positively correlated with BMI, which might explain the finding of elevated risk of hemorrhagic stroke among those with a low BMI. However, a definitive interpretation is not possible and further studies of the causal mechanisms linking low cholesterol and hemorrhagic stroke are needed.⁴³ In addition to cigarette smoking and preexisting disease, suggested mechanisms for the observed elevated risk of heart disease and cerebrovascular disease among individuals with low BMI include several cardiovascular abnormalities, such as reduced ventricular mass, valvular dysfunction, electrocardiographic changes, cardiac myofibril damage, and compromised immunity.²⁸

As was the case for cause-specific mortality and all-cause mortality, both high and low BMI values were related to excess risk of other-cause mortality. Although the specific causes of death are unknown, some interpretations are possible. As mentioned above, a high BMI is associated with an increased risk of major chronic diseases and more people are likely to die from the complications of such diseases. Elevated risk was also observed among those with a low BMI, which suggests that people with a low BMI have less resistance to various diseases, including infectious, respiratory, or inflammatory diseases.

In Western countries, more attention is paid to overweight and obesity than to low BMI. In a collaborative analysis of data from 57 prospective studies of almost 900 000 adults, mostly in Western Europe and North America, a U-shaped association, similar to ours, was observed for overall mortality, with the lowest risk at a BMI of 22.5 to 25 kg/m² after controlling for early follow-up and smoking status.²⁹ However, the PAF was calculated for higher BMIs only, which seemed to be largely causal. Based on the relative risks and recent population BMI values, approximately 29% of vascular deaths and 8% of neoplastic deaths in late middle age in the United States were attributable to having a BMI greater than 25 kg/m². In the United Kingdom, the corresponding proportions were approximately 23% and 6%. In France, a working group of the International Agency for Research on Cancer reported that the PAF of all-cancer mortality due to obesity and overweight—calculated by summing the results of obesity-related cancers

(ie, esophageal [adenocarcinoma], colorectal, kidney, corpus uteri, and breast [in postmenopausal women] cancers)—was 1.1% for men and 2.3% for women.⁴⁴

The elevated risk of mortality among those within the low BMI range was most apparent for diseases of other causes, whose past history was not deleted. This indicates that reverse causation, namely, bias caused by preexisting illness and attendant weight loss, might partially explain the observed findings. To eliminate this possibility, we excluded deaths within 5 years, the method most frequently proposed to control for possible illness-related weight loss (IRWL).²³ We found that most RRs were attenuated and that heterogeneity across studies improved in the low BMI range. In the high BMI range, some RRs were attenuated while others were not, CIs increased, and heterogeneity was unchanged or increased. Using this indirect approach, individuals with IRWL are not necessarily excluded and those who are excluded do not necessarily have IRWL, which could introduce new sources of bias. Because no adequate method has been established to control for the effect of reverse causation, it is not possible to totally eliminate or clearly reveal the magnitude of the effect. However, the high prevalence of lean people in Japan indicates that a low BMI might be associated with mortality risk. In a pooled analysis of more than 1 million Asians, Zheng et al observed that underweight was associated with a substantially increased risk of death in all Asian populations.⁴ They indicated that inadequate or incomplete control of confounding or reverse-causation bias might, in part, explain this increased risk. As Flegal et al indicate in their recent study, there is a need for studies with a more restricted focus and greater detail. Such studies might consider weight change or develop new methods of causal modeling.⁴⁵

This study has several limitations. First, measures of abdominal obesity, such as waist circumference and waist-to-hip ratio, were not available. In the European Prospective Investigation on Cancer prospective study, both waist circumference and waist-to-hip ratio were strongly associated with risk of death, independent of BMI.⁴⁶ Therefore, the number of deaths attributable to all adiposity-related factors is probably greater than the present estimates. Second, the present BMI calculation was based on self-reported values. To minimize the effect of unreliable reporting, we excluded individuals reporting a BMI less than 14 or 40 kg/m² or higher. In the Takayama Study, the intraclass correlation coefficients between self-reported and measured height and weight in a subsample were 0.93 and 0.97 in both sexes, respectively.¹⁸ In the JPHC study (combined JPHC-I and II, corresponding to 31.3% of the pooled dataset), self-reported BMI was slightly lower than measured BMI. In comparing self-reported height and weight with available data from health check-ups (11 274 men and 21 196 women), the Spearman correlation coefficient was 0.89 and 0.90 for men and women, respectively.²¹ Similar underestimates of BMI, especially at higher weights, were

also observed in a Western population.⁴⁷ It is uncertain whether the same was true for the other 4 studies; however, excess risk was observed only for a BMI of 30 kg/m² or higher across most of the end points, and the abovementioned effect is not likely to be large. Third, we used only single-point measurements of BMI as an exposure and did not capture weight change during the period. Accumulating evidence suggests that both weight gain and loss in adult life are associated with increased risk of mortality. We have previously observed that mortality from all causes and cancer is elevated by a weight loss of 5 kg or more after age 20 years⁴⁸ and during middle age,⁴⁹ whereas mortality from cardiovascular disease is elevated by a weight loss of 5 kg or more after age 20 in men⁴⁸ and weight gain during middle age in women.⁴⁹ Our combined findings indicate that maintaining an adequate weight in adulthood may be an important strategy for improving mortality in Japan. Limitations might also exist due to the process used for handling missing values. We chose to create an indicator term for missing data for each covariate, which might have led to biased estimates of the overall effect of the study exposure.⁵⁰

The strength of this study is that it included most of the ongoing prospective studies in Japan, with overlapping birth generations and a similar survey time period. Therefore, pooling of these studies allows for a stable quantitative estimate of the impact of relative weight among Japanese. In addition, the categories of BMI and covariates used were identical among studies, which removes a potential source of heterogeneity that can occur in a meta-analysis of published literature.

In summary, the lowest risks of total mortality and mortality from major causes of diseases were observed at a BMI of 23 to 27 kg/m² for men and 21 to 27 kg/m² for women in middle-aged and elderly Japanese. Because there was no elevation of risk for a BMI of 21 to 23 in never-smoking men, we conclude that a BMI of 21 to 27 kg/m² is associated with the lowest mortality risk in both sexes.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the assistance of Izumi Suenaga.

Conflicts of interest: The authors declare that they have no competing interests.

Funding: This study was supported by a Grant for the Third Term Comprehensive Control Research for Cancer from the Ministry of Health, Labour and Welfare of Japan.

REFERENCES

- World Health Organization. Diet, nutrition, and the prevention of chronic diseases. Report of a Joint WHO/FAO Expert Consultation. WHO Technical Report Series Number 916. Geneva: World Health Organization; 2003.
- Low S, Chin MC, Ma S, Heng D, Deurenberg-Yap M. Rationale for redefining obesity in Asians. *Ann Acad Med Singapore*. 2009;38:66–9.
- WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet*. 2004;363:157–63.
- Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, et al. Association between body-mass index and risk of death in more than 1 million Asians. *N Engl J Med*. 2011;364:719–29.
- Tamakoshi A, Yatsuya H, Lin Y, Tamakoshi K, Kondo T, Suzuki S, et al; JACC Study Group. BMI and all-cause mortality among Japanese older adults: findings from the Japan collaborative cohort study. *Obesity (Silver Spring)*. 2010;18:362–9.
- Nagai M, Kuriyama S, Kakizaki M, Ohmori-Matsuda K, Sugawara Y, Sone T, et al. Effect of age on the association between body mass index and all-cause mortality: the Ohsaki cohort study. *J Epidemiol*. 2010;20:398–407.
- Matsuo T, Sairenchi T, Iso H, Irie F, Tanaka K, Fukasawa N, et al. Age- and gender-specific BMI in terms of the lowest mortality in Japanese general population. *Obesity (Silver Spring)*. 2008;16:2348–55.
- Kuriyama S, Ohmori K, Miura C, Suzuki Y, Nakaya N, Fujita K, et al. Body mass index and mortality in Japan: the Miyagi Cohort Study. *J Epidemiol*. 2004;14 Suppl 1:S33–8.
- Tsugane S, Sasaki S, Tsubono Y. Under- and overweight impact on mortality among middle-aged Japanese men and women: a 10-y follow-up of JPHC study cohort I. *Int J Obes Relat Metab Disord*. 2002;26:529–37.
- Miyazaki M, Babazono A, Ishii T, Sugie T, Momose Y, Iwahashi M, et al. Effects of low body mass index and smoking on all-cause mortality among middle-aged and elderly Japanese. *J Epidemiol*. 2002;12:40–4.
- Mizoue T, Inoue M, Wakai K, Nagata C, Shimazu T, Tsuji I, et al. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. *Am J Epidemiol*. 2008;167:1397–406.
- Inoue M, Sasazuki S, Wakai K, Suzuki T, Matsuo K, Shimazu T, et al. Green tea consumption and gastric cancer in Japanese: a pooled analysis of six cohort studies. *Gut*. 2009;58:1323–32.
- Tsugane S, Sobue T. Baseline survey of JPHC study—design and participation rate. *Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Diseases*. *J Epidemiol*. 2001;11(6 Suppl):S24–9.
- Tamakoshi A, Yoshimura T, Inaba Y, Ito Y, Watanabe Y, Fukuda K, et al. Profile of the JACC study. *J Epidemiol*. 2005;15 Suppl 1:S4–8.
- Tsuji I, Nishino Y, Tsubono Y, Suzuki Y, Hozawa A, Nakaya N, et al. Follow-up and mortality profiles in the Miyagi Cohort Study. *J Epidemiol*. 2004;14 Suppl 1:S2–6.
- Tsuji I, Nishino Y, Ohkubo T, Kuwahara A, Ogawa K, Watanabe Y, et al. A prospective cohort study on National Health Insurance beneficiaries in Ohsaki, Miyagi Prefecture, Japan: study design, profiles of the subjects and medical cost during the first year. *J Epidemiol*. 1998;8:258–63.
- Marugame T, Sobue T, Satoh H, Komatsu S, Nishino Y, Nakatsuka H, et al. Lung cancer death rates by smoking status: comparison of the Three-Prefecture Cohort study in Japan to the Cancer Prevention Study II in the USA. *Cancer Sci*. 2005;96:120–6.
- Shimizu N, Nagata C, Shimizu H, Kametani M, Takeyama N,

- Ohnuma T, et al. Height, weight, and alcohol consumption in relation to the risk of colorectal cancer in Japan: a prospective study. *Br J Cancer*. 2003;88:1038–43.
19. World Health Organization. International classification of diseases and health related problem, 10th revision. Geneva, Switzerland: World Health Organization; 1990.
 20. Baik I, Ascherio A, Rimm EB, Giovannucci E, Spiegelman D, Stampfer MJ, et al. Adiposity and mortality in men. *Am J Epidemiol*. 2000;152:264–71.
 21. Inoue M, Sobue T, Tsugane S; JPHC Study Group. Impact of body mass index on the risk of total cancer incidence and mortality among middle-aged Japanese: data from a large-scale population-based cohort study—the JPHC study. *Cancer Causes Control*. 2004;15:671–80.
 22. Rothman KJ, Greenland S, Lash TL. *Modern epidemiology*. 3rd ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008. p. 300–2.
 23. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. *N Engl J Med*. 1999;341:427–34.
 24. Verbeke G, Molenberghs G, editors. *Linear mixed models in practice—a SAS-oriented approach*. New York: Springer-Verlag; 1997.
 25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21:1539–58.
 26. Armitage P, Berry G. *Statistical methods in medical research*. 3rd ed. London: Blackwell Scientific Publications; 1994.
 27. Funada S, Shimazu T, Kakizaki M, Kuriyama S, Sato Y, Matsuda-Ohmori K, et al. Body mass index and cardiovascular disease mortality in Japan: the Ohsaki Study. *Prev Med*. 2008;47:66–70.
 28. Cui R, Iso H, Toyoshima H, Date C, Yamamoto A, Kikuchi S, et al; JACC Study Group. Body mass index and mortality from cardiovascular disease among Japanese men and women: the JACC study. *Stroke*. 2005;36:1377–82.
 29. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet*. 2009;373:1083–96.
 30. Ishii T, Momose Y, Esaki H, Une H. A prospective study on the relationship between body mass index and mortality in middle-aged and elderly people in Japan. *Nippon Koshu Eisei Zasshi*. 1998;45:27–34 (in Japanese).
 31. Wang Y, Jacobs EJ, Patel AV, Rodriguez C, McCullough ML, Thun MJ, et al. A prospective study of waist circumference and body mass index in relation to colorectal cancer incidence. *Cancer Causes Control*. 2008;19:783–92.
 32. McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. *Cancer Epidemiol Biomarkers Prev*. 2008;17:73–9.
 33. Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. cohort. *Cancer Epidemiol Biomarkers Prev*. 2005;14:459–66.
 34. Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. *Cancer Causes Control*. 2002;13:325–32.
 35. Stevens RJ, Roddam AW, Spencer EA, Pirie KL, Reeves GK, Green J, et al; Million Women Study Collaborators. Factors associated with incident and fatal pancreatic cancer in a cohort of middle-aged women. *Int J Cancer*. 2009;124:2400–5.
 36. Benson VS, Pirie K, Green J, Casabonne D, Beral V; Million Women Study Collaborators. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. *Br J Cancer*. 2008;99:185–90.
 37. Kuriyama S, Tsubono Y, Hozawa A, Shimazu T, Suzuki Y, Koizumi Y, et al. Obesity and risk of cancer in Japan. *Int J Cancer*. 2005;113:148–57.
 38. Ni Mhurchu C, Rodgers A, Pan WH, Gu DF, Woodward M; Asia Pacific Cohort Studies Collaboration. Body mass index and cardiovascular disease in the Asia-Pacific Region: an overview of 33 cohorts involving 310 000 participants. *Int J Epidemiol*. 2004;33:751–8.
 39. Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. *Am J Med*. 1995;98 1A:27S–32S.
 40. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. *Am J Epidemiol*. 1997;146:214–22.
 41. Hall WD, Ferrario CM, Moore MA, Hall JE, Flack JM, Cooper W, et al. Hypertension-related morbidity and mortality in the southeastern United States. *Am J Med Sci*. 1997;313:195–209.
 42. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. *N Engl J Med*. 1989;320:904–10.
 43. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. *Circulation*. 1992;86:1046–60.
 44. World Health Organization. International Agency for Research on Cancer. Attributable causes of cancer in France in the year 2000. IARC Working Group Reports Vol 3; Section B5: Obesity and overweight. p. 60–4.
 45. Flegal KM, Graubard BI, Williamson DF, Cooper RS. Reverse causation and illness-related weight loss in observational studies of body weight and mortality. *Am J Epidemiol*. 2011;173:1–9.
 46. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General and abdominal adiposity and risk of death in Europe. *N Engl J Med*. 2008;359:2105–20.
 47. Niedhammer I, Bugel I, Bonenfant S, Goldberg M, Leclerc A. Validity of self-reported weight and height in the French GAZEL cohort. *Int J Obes Relat Metab Disord*. 2000;24:1111–8.
 48. Chei CL, Iso H, Yamagishi K, Inoue M, Tsugane S. Body mass index and weight change since 20 years of age and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based Study. *Int J Obes (Lond)*. 2008;32:144–51.
 49. Nanri A, Mizoue T, Takahashi Y, Noda M, Inoue M, Tsugane S; Japan Public Health Center-based Prospective Study Group. Weight change and all-cause, cancer and cardiovascular disease mortality in Japanese men and women: the Japan Public Health Center-Based Prospective Study. *Int J Obes (Lond)*. 2010;34:348–56.
 50. Rothman KJ, Greenland S, Lash TL. *Modern epidemiology*. 3rd ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008. p. 219.

Lung Cancer Risk and Consumption of Vegetables and Fruit: An Evaluation Based on a Systematic Review of Epidemiological Evidence from Japan

Kenji Wakai^{1,*}, Keitaro Matsuo², Chisato Nagata³, Tetsuya Mizoue⁴, Keitaro Tanaka⁵, Ichiro Tsuji⁶, Shizuka Sasazuki⁷, Taichi Shimazu⁷, Norie Sawada⁷, Manami Inoue⁷ and Shoichiro Tsugane⁷ for the Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan[†]

¹Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, ²Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, ³Department of Epidemiology and Preventive Medicine, Gifu University Graduate School of Medicine, Gifu, ⁴Department of Epidemiology and International Health, National Center for Global Health and Medicine, Tokyo, ⁵Department of Preventive Medicine, Saga University Faculty of Medicine, Saga, ⁶Division of Epidemiology, Department of Public Health and Forensic Medicine, Tohoku University Graduate School of Medicine, Sendai and ⁷Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan

*For reprints and all correspondence: Kenji Wakai, Department of Preventive Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. E-mail: wakai@med.nagoya-u.ac.jp

[†]Research group members are listed in the Appendix.

Received September 29, 2010; accepted February 9, 2011

Objective: Clinical trials of β -carotene supplementation and recent large-scale prospective studies have called into question the protective effects of vegetable and fruit consumption against lung cancer. To re-assess this issue, we reviewed data from Japanese epidemiological studies.

Methods: Original data were obtained from searches of MEDLINE and the Japana Centra Revuo Medicina (Ichushi) database. The associations were assessed based on their magnitude and the strength of the evidence, together with their biological plausibility as previously evaluated by the International Agency for Research on Cancer.

Results: We identified six cohort studies and four case–control studies on the consumption of vegetables and/or fruit. We focused on fruit and green-yellow vegetables as food items, as they were included in more of the studies, and insufficient data were available on other types of vegetables. Among the three cohort and two case–control studies that reported on green-yellow vegetables, only one of each study type showed a weak inverse association between lung cancer risk and their consumption. Two of the four cohort studies and one (or possibly two) of the four case–control studies demonstrated a weak inverse correlation between lung cancer risk and fruit consumption. Meta-analysis for fruit consumption revealed a summary relative risk that was significantly smaller than unity.

Conclusions: Our analysis of the Japanese epidemiological data showed that fruit consumption possibly decreased the risk of lung cancer, but found insufficient evidence of a link with vegetable consumption. Further prospective studies should assess the effects of consuming these food groups.

Key words: systematic review – vegetables – fruit – lung neoplasms – Japanese